We used an immunoperoxidase procedure to examine the tissue distribution of the platelet a-granule membrane protein, GMP-140. In addition to its presence in megakaryocytes and platelets, GMP-140 antigen was found in vascular endothelial cells of diverse human organs, but it was not detected in other types of secretory cells. 35S]Cysteine-labeled human umbilical vein endothelial cells synthesized a GMP-140 molecule containing complex N-linked oligosaccharides similar to those previously demonstrated in platelets and the megakaryocytic HEL cell line. Using an immunogold procedure on frozen thin sections of endothelial cells, we found GMP-140 antigen to be localized to membranes of electron-dense storage granules. In double-label experiments there was colocalization of GMP-140 with vWf, indicating that these granules are Weibel-Palade bodies. When endothelial cells were stimulated with histamine, GMP-140 rapidly redistributed to the plasma membrane. Immunoassays of cell lysates indicated that, relative to total cell protein, less GMP-140 is present in human umbilical vein endothelial cells than in platelets. The restricted expression of GMP-140 in secretory granules of platelets and endothelium suggests that it has a specific function in the vascular system rather than a general role related to inducible secretion.
Introduction
GMP-140 is a platelet a-granule membrane protein of M, 140 ,000 that redistributes to the plasma membrane during platelet activation and degranulation (1) (2) (3) (4) (5) . The protein is cysteine-rich and contains several complex N-linked oligosaccharide chains (6) . Protease accessibility studies suggest that most of the mass of GMP-140 is exposed on the extracytoplasmic face of the membrane (6) . The function of GMP-140 is not known and its distribution in cells other than platelets A preliminary report of this study was presented at the Annual Meeting of the American Society of Hematology, Washington, DC, 6 December 1987, and was published in abstract form (1987. Blood. and megakaryocytes (7) has not been established. Ifthe protein is located in storage granules of diverse cells, it might have a conserved function related to inducible secretion. Alternatively, restriction of GMP-140 expression to secretory cells found in blood would suggest a function specific to the vascular system.
In this study we used an immunoperoxidase procedure to examine the distribution of GMP-140 in a variety of human tissues. In addition to its presence in megakaryocytes and platelets, GMP-140 antigen was detected in vascular endothelial cells but not in a variety of other cell types examined. We have documented the synthesis of GMP-140 in endothelial cells and have localized the protein to the membranes of Weibel-Palade bodies, the intracellular storage granules for vWf.
Methods
Antibodies. The MAbs S12 (1, 3) and W40 (6) , both directed against GMP-140, and monospecific rabbit polyclonal antiserum to GMP-140 (3) were prepared as described previously. Tab, a MAb to platelet glycoprotein Ilb, has been previously characterized (8) . MAbs were used as purified IgG in 0.20 M sodium phosphate, pH 7.4, and 0.15 M sodium chloride. Affinity-purified polyclonal rabbit anti-human vWf antibodies were obtained from Dako Corp. (Santa Barbara, CA).
Immunoperoxidase procedures. Immunoperoxidase detection of antigens in plastic-embedded sections of human tissues was performed as described previously (7) .
Culture ofendothelial cells. Human umbilical vein endothelial cells were isolated and grown by a modification of the procedure ofJaffe et al. (9) . The cells were cultured in medium 199 (K. C. Biologicals, Kansas City, MO) containing 25 mM Hepes buffer supplemented with 100 U/ml penicillin, 100 ,tg/ml streptomycin, 2 mM glutamine (K. C. Biologicals), 20% fetal bovine serum (K. C. Biologicals), 50 gg/ml heparin, and 60 ,g/ml endothelial cell growth supplement (Collaborative Research Inc., Lexington, MA). Only primary or first-passage cultures at or near confluence were used. Some primary cultures for frozen thin sections (see below) were a gift from Dr. Israel Charo and Dr. William Isenberg (the Gladstone Foundation, University of California at San Francisco).
Metabolic labeling ofendothelial cells. GMP-140 was immunoprecipitated from [35S]cysteine-labeled lysates of human endothelial cells and analyzed by SDS-PAGE as described previously in studies ofHEL cells (6) , except that the endothelial cells were grown in 75-cm2 flasks instead of cluster dishes. As a control, '25I-labeled GMP-140 from human platelets was analyzed concurrently (6) . Incubation of immunoprecipitates with endo-,B-N-acetylglucosaminidase H (endo H)' was performed as described previously (6) .
Immunocytochemical techniques on frozen thin sections. Monolayers of human umbilical vein endothelial cells were fixed in 4 or 8% paraformaldehyde in Nakane's buffer, embedded in 2.1 M sucrose, and frozen. Sections were prepared as previously described (3). The primary antibody was polyclonal antiserum to GMP-140 used at a dilution of 1:100. The immunogold probe, goat anti-rabbit IgG-gold (GAR-5 [5 nm] or GAR-O0 [10 nm]; Janssen Pharmaceutica, Beerse, Belgium) was used at a dilution of 1:50. Nonimmune rabbit serum was used in place of the primary antiserum to act as a control. A double-labeling experiment to simultaneously localize GMP-140 and vWf was performed using protein A, as described by Slot and Geuze (10) . Polyclonal antiserum to GMP-140 was applied and labeled with 5-nm gold particles coupled to protein A (protein A-5; Janssen Pharmaceutica). 0.05 mg/ml free protein A was then added. Next, polyclonal antibodies to vWf( 1:100 dilution) were applied, followed by 10-nm gold particles coupled to protein A (protein A-10; Janssen Pharmaceutica). The protein A-colloidal gold reagents were used for the double-label studies because they gave more precise localization due to the 1:1 binding ratio with primary antibody. The antibody-gold complex (GAR-5 or GAR-IO) was used in other experiments because of its increased sensitivity due to binding of multiple secondary antibodies to the same primary antibody; this binding property, however, resulted in some clumping of gold particles leading to less precise antigen localization.
In some experiments confluent monolayers were prewarmed to 370C in HBSS containing 10 Table I , were examined for the presence of GMP-140 antigen with a sensitive avidin-biotin immunoperoxidase procedure. GMP-140 was detected in bone marrow megakaryocytes ( Fig. 1 a and reference 7) , platelets (Fig. 1, a and e), and endothelial cells lining blood vessels of multiple organs (Fig. 1, b-e and Table I ). Endothelial cell GMP-140 was detected by the MAb S 12 and by polyclonal antibodies to GMP-140. Nonimmune rabbit serum and MAbs of irrelevant specificity did not label endothelial cells. These negative controls did demonstrate occasional weak staining of other cell types, probably because of endogenous biotin. Only staining above this background was considered positive. The GMP-140 antigen visualized in endothelium was not due to adherence of platelets, since Tab, MAb that recognizes the platelet-specific glycoprotein IIb (8, 13), stained platelets in the lumen ofblood vessels but did not label endothelial cells (Fig. 1 f) . In contrast, antibodies to glycoprotein IIIa, which is present in both platelets and endothelial cells, stained both cell types (7) .
Endothelial cell GMP-140 antigen was detected in greatest abundance in small veins and venules, although patchy distribution was occasionally noted in small arteries, arterioles, and very rarely in capillaries. The endothelial distribution of GMP-140 demonstrated some differences from that previously reported for thrombomodulin, an endothelial cell membrane cofactor for protein C activation (14) . Unlike thrombomodulin, GMP-140 antigen was detected in some blood vessels of brain and in high endothelial cells of lymph nodes (Fig. 1 d) but was not found in lymphatics or in syncytiotrophoblast lining cells of placenta. (Fig. 1 a) . Moreover, we did not detect antigen in a variety of other cells that contain storage granules whose contents are released after stimulation of the cell (Table I) . These included adrenal gland, pituitary, pancreas, brain, breast, and salivary gland.
Biosynthesis of GMP-140 in endothelial cells. To determine whether endothelial cells synthesize GMP-140, we immunoprecipitated lysates of [35S]cysteine-labeled human umbilical vein endothelial cells with antibodies to GMP-140 and examined the immunoprecipitates by SDS-PAGE and fluorography. Fig. 2 demonstrates that in lysates ofcells pulsed for 3 h, polyclonal antibodies to GMP-140 (lane A) immunoprecipitated a precursor molecule that migrated faster than platelet GMP-140 (lane E). The MAb S12 and W40 also precipitated this molecule (not shown). When the labeled cells were chased for 16 h before lysis in medium containing unlabeled cysteine, the antibodies precipitated an endothelial cell protein that comigrated with platelet GMP-140 (lanes B-D). We have previously shown that HEL cells, which share features of megakaryocytes (15) , synthesize a 125-kD precursor of GMP-140 which is converted to a 140-kD form that comigrates with platelet GMP-140 (6 Fig. 3 , endo H decreased the Mr of the precursor but did not change the Mr of the mature molecule. These findings suggest that endothelial cells, like HEL cells and presumably megakaryocytes, synthesize a precursor of GMP-140 that contains high mannose N-linked oligosaccharides. The high mannose chains are then converted to the complex type in the Golgi apparatus.
Subcellular localization ofGMP-140 in endothelial cells. In unstimulated platelets, GMP-140 is localized in the membranes of a-granules (3, 4) . To determine whether endothelial cell GMP-140 is also located in secretory storage granules, we used an immunogold procedure on frozen thin sections of unstimulated human umbilical vein endothelial cells. Immunogold label was found in intracellular electron-dense granules, mainly along the membranes, but was not found on the plasma membrane (Figs. 4, a and b, and 5) . Smaller amounts of label were also found in fragmented endoplasmic reticulum (ER) and on Golgi cisternae membranes. Some of the granules containing immunogold marker for GMP-140 had images suggestive of the tubular, periodic matrix characteristic of Weibel-Palade bodies, the organelles where vWf is concentrated and converted into high molecular weight multimers (17) (18) (19) (20) (21) . However, the frozen thin section procedure did not provide optimal preservation to allow classification of the granules as Weibel-Palade bodies by morphologic criteria. We therefore performed double-label experiments with antibodies to both GMP-140 and vWf, as described in Methods. The smaller gold label for GMP-140 was again detected mainly along the membranes of granules, while the larger gold label for vWf was more widely distributed over the matrix of the granules (Fig. 4 c) . As with GMP-140, the major concentration of vWf was in granules with lesser amounts detected in fragmented ER and Golgi cisternae. The colocalization ofboth GMP-140 and vWf to the same granules establishes that GMP-140 is also located in Weibel-Palade bodies.
vWf stored in Weibel-Palade bodies is rapidly secreted from endothelial cells stimulated with agonists such as thrombin (22) , phorbol myristate acetate (20) , histamine (23) , and complement proteins C5b-9 (24). This suggests that after endothelial cell activation GMP-140 might redistribute from the membranes of Weibel-Palade bodies to the plasma membrane in a manner analogous to its redistribution to the cell surface pm-. after platelet activation (1) (2) (3) (4) (5) (17) (18) (19) (20) (21) (22) (23) (24) . The inducible secretion of vWf is thought to occur during fusion of membranes of Weibel-Palade bodies with the plasma membrane (32) . This process is supported by the immunogold labeling experiments which demonstrated rapid redistribution of GMP-140 to the plasma membrane of histamine-stimulated cells. Elsewhere, we have quantitated the inducible endothelial redistribution of GMP-140 and examined its kinetics in detail (24, 33). These studies, in conjunction with the current report, suggest that antibodies to GMP-140 will prove useful as markers for early activation events in endothelial cells, similar to their previously documented utility for assessing platelet activation in vivo and in vitro (12, (34) (35) (36) .
Since GMP-140 rapidly shifts from the membranes of secretory granules to the surface of stimulated platelets and endothelial cells, it may function as an important receptor at sites of inflammation or vascular injury, where these cells are likely to be activated. We have recently determined the primary structure of GMP-140 by cDNA cloning and protein sequencing (37) . The protein contains a number of discrete domains, including a lectinlike region, an epidermal growth factor domain, and nine tandem consensus repeats related to those found in complement-binding proteins. These domains suggest that GMP-140 might have functions related to cell adhesion and inflammation. This possibility is supported by the remarkable structural similarity of GMP-140 to ELAM-1, a cytokine-inducible endothelial cell receptor that mediates the adhesion of neutrophils to endothelium at sites of inflammation (38) . ELAM-l contains a lectin domain, an epidermal growth factor domain, and six complement-binding repeats (39) . It is of interest that the migration of leukocytes across endothelium in response to inflammatory stimuli occurs primarily in small veins and venules (40) . These are precisely the Figure 6 . Higher magnification of two stimulated endothelial cells fixed 1 min after addition of histamine and then labeled with immunogold under conditions identical to those in Fig. 5 . Note the marked disturbance of the cell surface with numerous microvilli and the expression of immunogold label for GMP-140 on the plasma membrane. There is a junctional complex (j) between the two endothelial cells and the immunolabel is mainly on the apical surface rather than the lateral surface. An intracellular Weibel-Palade body (WP) can also be seen. X88,000.
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